Brc Investment Management adds Bristol-Myers Squibb Co (BMY) to its portfolio

Bristol-Myers Squibb Co (BMY) : Brc Investment Management added new position in Bristol-Myers Squibb Co during the most recent quarter end. The investment management firm now holds 296,168 shares of Bristol-Myers Squibb Co which is valued at $21,377,406 , the company said in a statement filed on Apr 26, 2016 with the SEC.Bristol-Myers Squibb Co makes up approximately 3.17% of Brc Investment Management’s portfolio.

Bristol-Myers Squibb Co closed down -0.22 points or -0.30% at $71.96 with 77,39,057 shares getting traded on Monday. Post opening the session at $72.19, the shares hit an intraday low of $71.49 and an intraday high of $72.34 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

Other Hedge Funds, Including , Douglass Winthrop Advisors boosted its stake in BMY in the latest quarter, The investment management firm added 800 additional shares and now holds a total of 33,828 shares of Bristol-Myers Squibb Co which is valued at $2,441,705. Bristol-Myers Squibb Co makes up approx 0.17% of Douglass Winthrop Advisors’s portfolio.Neville Rodie Shaw Inc boosted its stake in BMY in the latest quarter, The investment management firm added 1,150 additional shares and now holds a total of 105,290 shares of Bristol-Myers Squibb Co which is valued at $7,164,985. Bristol-Myers Squibb Co makes up approx 0.86% of Neville Rodie Shaw Inc’s portfolio.Newman Dignan Sheerar reduced its stake in BMY by selling 335 shares or 0.94% in the most recent quarter. The Hedge Fund company now holds 35,443 shares of BMY which is valued at $2,411,896. Bristol-Myers Squibb Co makes up approx 1.74% of Newman Dignan Sheerar’s portfolio.

On the company’s financial health, Bristol-Myers Squibb Co reported $0.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $0.65. The company had revenue of $4391.00 million for the quarter, compared to analysts expectations of $4268.65 million. The company’s revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.71 EPS.

Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Company shares were Reiterated by UBS on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 80 from a previous price target of $73 .Company shares were Reiterated by Barclays on Apr 29, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 75 from a previous price target of $70 .Societe Generale Initiated Bristol-Myers Squibb Co on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $48.

Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.

Leave a Reply

Bristol-Myers Squibb Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Bristol-Myers Squibb Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.